Providers/Grant Support
This activity is supported by an educational grant from Blueprint Medicines.
Credits Available
- Physicians — maximum of 0.5 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Program Overview
Indolent systemic mastocytosis (ISM) can present with a wide range of systemic and cutaneous symptoms, making timely diagnosis challenging. In this 20-minute Seminar in Depth, expert faculty review practical approaches to recognizing and diagnosing ISM and highlight emerging targeted therapies designed to rapidly control mast cell–driven disease burden.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the heterogeneous and cutaneous clinical presentation of indolent systemic mastocytosis (ISM) as it relates to early diagnosis
- Identify patients with ISM based on the 2023 National Comprehensive Cancer Network (NCCN) guidelines
- Describe new and emerging targeted therapies available for the treatment of ISM
Faculty
Matthew Giannetti, MD
Assistant Professor of Medicine
Harvard Medical School, Brigham and Women's Hospital
Boston, MA
Lauren Madigan, MD
Associate Professor
Derpartment of Dermatology, University of Utah
Salt Lake City, UT
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Matthew P. Giannetti, MD
Consultant: Blueprint Medicines, Cogent Biosciences, Nemagen Discoveries, Imagine Bio
Lauren Madigan, MD
Advisory Board: Blueprint Medicines
Speakers’ Bureau or Honoraria: Blueprint Medicines
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
The Institute requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]